RL
RLYB
Rallybio Corp
$15.92
0.00%
$84.3M
No data for this timeframe.
Vol
Market Cap$84.3M
Cap SizeMicro Cap
Inst. Holders14 funds
Inst. Value$13.9M
Insider Activity8B / 1S
Insider Net $$905.4K
SEC Reports3
Recent Activity
Jun 1, 2026
SEC
Rallybio Corp (RLYB) filed this 425 communication to confirm the definitive merger agreement entered into on May 31, 202
425 — Impact 7/10
Jun 1, 2026
SEC
Rallybio Corp (RLYB) entered into a definitive merger agreement to be acquired by Avenzo Therapeutics in a reverse-merge
8-K — Impact 7/10
May 19, 2026
Insider
ADAR1 Capital Management, LLC bought 10,000 shares
10%+ Owner @ $13.98 ($139.8K)
May 18, 2026
Insider
ADAR1 Capital Management, LLC bought 6,009 shares
10%+ Owner @ $13.98 ($84.0K)
May 15, 2026
Insider
ADAR1 Capital Management, LLC bought 100 shares
10%+ Owner @ $13.80 ($1.4K)
May 12, 2026
earnings_calendar
RLYB Q1 2026 Earnings Before Market Open — 2026-05-12
May 4, 2026
SEC
Candid Therapeutics terminated its merger agreement with Rallybio to enter a deal with UCB S.A. Rallybio receives a $50M
8-K — Impact 6/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 15, 2025 | Jones Trading | DOWNGRADE | Buy → Hold |
| Apr 9, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Mar 17, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 12, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 13, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.28 | $-1.28 — $-1.28 | 27% YoY | 1 |
| Next Q | $-1.44 | $-1.44 — $-1.44 | -150% YoY | 1 |
| Current FY | $-5.52 ▼ -2.2% | $-5.52 — $-5.52 | -247% YoY | 1 |
| Next FY | $-3.60 | $-3.60 — $-3.60 | 22% YoY | 1 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $7.1M | — |
| BALYASNY ASSET MANAGEMENT L.P. | $3.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.0M | — |
| Mariner, LLC | $453.6K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | ADAR1 Capital | BUY | $139.8K |
| May 18, 2026 | ADAR1 Capital | BUY | $84.0K |
| May 15, 2026 | ADAR1 Capital | BUY | $1.4K |
| May 13, 2026 | ADAR1 Capital | BUY | $56.3K |
| May 12, 2026 | ADAR1 Capital | BUY | $11.1K |
14 institutional holders with $13.9M total value (1,552,968 shares) as of 2026-Q1. Top holders: FMR, BALYASNY, RENAISSANCE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 793,451 | $7.1M | 51.1% | — |
| 2 | BALYASNY ASSET MANAGEMENT L.P. | 376,573 | $3.4M | 24.2% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 156,527 | $1.4M | 10.1% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 112,040 | $1.0M | 7.2% | — |
| 5 | Mariner, LLC | 50,566 | $453.6K | 3.3% | — |
| 6 | CITADEL ADVISORS LLC | 19,886 | $178.4K | 1.3% | — |
| 7 | BlackRock, Inc. | 17,486 | $156.8K | 1.1% | — |
| 8 | VANGUARD FIDUCIARY TRUST CO | 13,547 | $121.5K | 0.9% | — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 11,280 | $101.2K | 0.7% | — |
| 10 | Vanguard Global Advisers, LLC | 1,442 | $12.9K | 0.1% | — |
| 11 | MORGAN STANLEY | 126 | $1.1K | 0.0% | — |
| 12 | WELLS FARGO & COMPANY/MN | 37 | $332.00 | 0.0% | — |
| 13 | Allworth Financial LP | 6 | $54.00 | 0.0% | — |
| 14 | DANSKE BANK A/S | 1 | $9.00 | 0.0% | — |
4 unique insiders with 12 transactions. Net insider value: $905.4K ($909.4K bought, $4.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 10,000 | $13.98 | $139.8K |
| May 18, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 6,009 | $13.98 | $84.0K |
| May 15, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 100 | $13.80 | $1.4K |
| May 13, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 4,081 | $13.80 | $56.3K |
| May 12, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 800 | $13.83 | $11.1K |
| May 11, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 5,100 | $14.00 | $71.4K |
| May 5, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 35,101 | $14.00 | $491.3K |
| May 4, 2026 | ADAR1 Capital Management, LLC | 10%+ Owner | BUY | 3,900 | $13.90 | $54.2K |
| Feb 23, 2026 | Lieber Jonathan I | Chief Financial Officer | SELL | 789 | $5.06 | $4.0K |
| Feb 18, 2026 | Lieber Jonathan I | Chief Financial Officer | AWARD | 2,500 | — | — |
| Feb 18, 2026 | MACKAY MARTIN | Director | AWARD | 18,055 | $3.60 | $65.0K |
| Feb 18, 2026 | HUNT RONALD | Director | AWARD | 14,305 | $3.60 | $51.5K |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.7/10.
BULLISH
425
7/10
Rallybio Corp (RLYB) filed this 425 communication to confirm the definitive merger agreement entered
Jun 1, 2026
BULLISH
8-K
7/10
Rallybio Corp (RLYB) entered into a definitive merger agreement to be acquired by Avenzo Therapeutic
Jun 1, 2026
MIXED
8-K
6/10
Candid Therapeutics terminated its merger agreement with Rallybio to enter a deal with UCB S.A. Rall
May 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2025): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.28 | $-1.28 | $-1.28 | 27.3% | +0.0% | — | $0.0B | -100.0% | 1 |
| Next Q 2026-09-30 |
$-1.44 | $-1.44 | $-1.44 | -150.0% | +0.0% | — | $0.0B | -100.0% | 1 |
| Current FY 2026-12-31 |
$-5.52 | $-5.52 | $-5.52 | -247.2% | -2.2% | — | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-3.60 | $-3.60 | $-3.60 | 21.7% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.280 | |
| 7d ago | $-1.280 | |
| 30d ago | $-1.280 | |
| 60d ago | $-1.280 | |
| 90d ago | $-1.280 |
8 analyst firms have rated this stock: 0 upgrades, 4 downgrades, 7 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 15, 2025 | Jones Trading | DOWNGRADE | Buy | Hold |
| Apr 9, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Mar 17, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 12, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 22, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 30, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 26, 2024 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 15, 2024 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| May 10, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 19, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Apr 18, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Apr 11, 2024 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 13, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Mar 13, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 7, 2024 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Feb 7, 2024 | Wedbush | MAINTAIN | Outperform | Outperform |
| Feb 7, 2024 | Jefferies | DOWNGRADE | Buy | Hold |
| Feb 7, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 21, 2023 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Nov 29, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 10, 2023 | Wedbush | MAINTAIN | Outperform | Outperform |
| Nov 10, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 5, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Sep 5, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 10, 2023 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jul 25, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jun 30, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 26, 2023 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Jun 26, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 17, 2023 | HC Wainwright & Co. | INITIATE | — | Buy |
| Apr 10, 2023 | Wedbush | INITIATE | — | Outperform |
| Feb 22, 2023 | JMP Securities | REITERATE | — | Market Outperform |
| Dec 9, 2022 | JP Morgan | INITIATE | — | Overweight |
| Aug 9, 2022 | JMP Securities | MAINTAIN | — | Market Outperform |
| Mar 16, 2022 | JMP Securities | MAINTAIN | — | Market Outperform |
| Feb 22, 2022 | JMP Securities | INITIATE | — | Market Outperform |
| Aug 23, 2021 | Evercore ISI Group | INITIATE | — | Outperform |
| Aug 23, 2021 | Cowen & Co. | INITIATE | — | Outperform |
| Aug 23, 2021 | Jefferies | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Mar 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| Feb 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| Jan 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
RLYB Q1 2026 Earnings Before Market Open — 2026-05-12
Apr 1, 2026
Clinical Trial
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Phase Phase 2 — TERMINATED
Mar 17, 2026
earnings_calendar
RLYB Q4 2025 Earnings After Market Close — 2026-03-17